
ABREVIATED CURRICULUM VITAE

LARISA HUMMA CAVALLARI

March 2010

PERSONAL DATA

Office Address: Department of Pharmacy Practice (MC 886)
College of Pharmacy, University of Illinois at Chicago
833 South Wood Street, Room 164
Chicago, Illinois 60612-7230
E-mail - humma@uic.edu

Telephone: Office - (312) 996-0886
Fax - (312) 996-0379

EDUCATION

1986-1989 Pre-pharmacy, Georgia Southern University, Statesboro, Georgia

1989-1991 Bachelor of Science in Pharmacy, *Summa Cum Laude*
University of Georgia, Athens, Georgia

1995-1997 Doctor of Pharmacy, University of Georgia, Athens, Georgia

POST-DOCTORAL TRAINING

1997-1998 *ASHP Accredited Pharmacy Practice Residency*
Veterans Affairs Medical Center, Memphis, Tennessee

1998-2000 *Cardiovascular Pharmacogenomics Research Fellowship*
The University of Florida, Gainesville, Florida

LICENSURE AND BOARD CERTIFICATION

Pharmacy Licensure: GA, IL

Board Certification: Board Certified Pharmacotherapy Specialist

PROFESSIONAL APPOINTMENTS

1/2001 – 07/2009 Assistant Professor, Department of Pharmacy Practice
University of Illinois at Chicago, Chicago, Illinois

08/2009 – present Associate Professor, Department of Pharmacy Practice
University of Illinois at Chicago, Chicago, Illinois

PROFESSIONAL EXPERIENCE

08/1991 – 06/1997 Community Pharmacist, Phar-Mor Pharmacy, Eckerd Drugs

07/1997 – 06/1998 Clinical Pharmacist, VA Medical Center, Memphis, TN

07/1998 – 12/2000	Clinical Pharmacist, Heart Failure Clinic, Shands Hospital at the University of Florida, Gainesville, FL
07/2000 – 12/2000	Staff Pharmacist, VA Medical Center, Gainesville, FL
03/2001 – 03/2003	Clinical Pharmacist, Cardiology / Critical Care Unit, University of Illinois at Chicago Medical Center, Chicago, IL
01/2004 – Present	Clinical Pharmacist, Antithrombosis Clinic, University of Illinois at Chicago Medical Center, Chicago, IL

RESEARCH COLLABORATIONS

Member, The International Warfarin Pharmacogenetics Consortium, an international collaboration of 22 research groups and the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) to combine warfarin pharmacogenetics data in order to address questions that cannot be answered with single, geographically-isolated studies.

SELECTED PUBLICATIONS

Original Articles

1. **Humma LM**, Farmerie WG, Wallace MR, Johnson JA. Sequencing of β_2 -adrenoceptor gene PCR products using Taq BigDye-Terminator chemistry results in inaccurate base-calling. *BioTechniques* 2000;29(5):962-964, 966, 968.
2. Wang J, Mougey EB, David CJ, **Humma LM**, Johnson JA, Lima JJ, Sylvester JE. Determination of human β_2 -adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. *Am J Pharmacogenomics* 2001;1(4):315-322.
3. **Humma LM**. Predicting adverse drug reactions using pharmacogenetics. (Invited review) *Clin Trend Pharm Practice*. 2001;15(8):104-123.
4. **Humma LM**, Puckett BJ, Richardson HE, Lejeune BL, McNamara DM, Pepine CJ, Johnson JA. Effects of β_1 -adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. *Am J Cardiol* 2001;88(9):1034-1037.
5. Johnson JA, **Humma LM**. Pharmacogenetics of cardiovascular drugs. (Invited review) *Brief Funct Genomic Proteomic* 2002;1(1):66-79.
6. **Humma LM**, Terra, SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. (Invited review) *Am J Health- Syst Pharm* 2002;59(13):1241-1252.
7. **Humma LM**. Predicting drug response with pharmacogenomics. (Invited review) *Applied Genomic Proteomic* 2002;1(3):151-168.
8. **Humma LM**, Richardson HE, Lewis JF, McGorray, SP, Pepine CJ, Johnson JA. Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of β -blocker withdrawal: A Report from the Women's Ischemic Syndrome Evaluation Study. *Pharmacotherapy* 2002;22(8):939-946.
9. Andrisin TE, **Humma LM**, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. *Pharmacotherapy* 2002;22(8):954-960.

10. **Cavallari LH**, Fashingbauer LA, Beitelshes AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. *Pharmacotherapy* 2004;24(6):750-756.
11. Aquilante CL, (**Cavallari**) Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. *Am J Cardiol* 2004;94(4):535-538.
12. Southworth MR, **Cavallari LH**. New treatment option for heart failure patients: Eplerenone. (Invited review) *J Cardiovasc Nurs* 2004;19(6):390-395.
13. Terra SG, McGorray SP, Wu R, McNamara DM, **Cavallari LH**, Walker JR, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, Johnson JA. Association between β -adrenergic receptor polymorphisms and their G-protein coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. *Int J Obes (Lond)* 2005;29(7):746-754.
14. Johnson JA, **Cavallari LH**. Cardiovascular Pharmacogenomics. (Invited review) *Exp Physiol* 2005;90(3):283-289.
15. **Cavallari LH**, Helgason CM, Brace LD, Viana, MA, Nutescu EA. Sex differences in the antiplatelet effect of aspirin after stroke. *Ann Pharmacother* 2006;40(5):812-817.
16. **Cavallari LH**, Groo VL, Momary KM, Fontana D, Viana MAG, Vaitkus P. Racial difference in potassium response to spironolactone in heart failure. *Congest Heart Fail* 2006;12(4):200-205.
17. **Cavallari LH**, Momary KM, Groo VL, Viana, MAG, Camp JR, Stamos TD. β -blocker dose is associated with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. *Pharmacotherapy* 2007;27(6):801-812.
18. **Cavallari LH**, Groo VL, Momary KM, Stamos TD, Vaitkus PT. Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure. *Congest Heart Fail* 2007;13(5): 275-279.
19. Momary KM, Shapiro NL, Viana MAG, Nutescu EA, Helgason CM, **Cavallari LH**. Factors influencing warfarin dose requirements in African Americans. *Pharmacogenomics* 2007;8(11):1535-1544.
20. Shord SS, **Cavallari LH**, Viana MAG, Momary K, Neceskas J, Molokie RE, Deyo K, Patel SR. Cytochrome P450 2C9 mediated metabolism in people with and without cancer. *Internat J Clin Pharmacol Ther* 2008;46(7):365-374.
21. Wang D, Chen H, Momary KM, **Cavallari LH**, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (*VKORC1*) affects gene expression and warfarin dose requirement. *Blood* 2008;112(4):1013-1021.
22. **Cavallari LH**, Fashingbauer LA, Camp JR, King ST, Geenen DL. Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. *J Renin Angiotensin Aldosterone Syst* 2008;9(3):146-153.
23. Aquilante CL, Yarandi HN, **Cavallari LH**, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. *Pharmacogenomics J* 2008;8(6):408-415.
24. The International Warfarin Pharmacogenetics Consortium.* Estimation of the warfarin dose with clinical and pharmacogenetic data. *New Engl J Med* 2009;360(8):753-764. ***Author and data contributor.**

25. **Cavallari LH**, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA. Predictors of unstable anticoagulation in African Americans. *J Thromb Thrombolysis* 2009;27(4):430-437.
26. Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, **Cavallari LH**. Influence of cyclooxygenase-1 genotype on *ex-vivo* aspirin response in patients at risk for stroke. *Cerebrovascular Dis* 2009;27(6):585-593.
27. **Cavallari LH**, Limdi NA. Warfarin pharmacogenomics. (Invited review) *Curr Opin Mol Ther* 2009;11(3):243-251.
28. Shord SS, **Cavallari LH**, Gao W, Jeong H, Deyo K, Patel SR, Camp JR, Labott SM, Molokie RE. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. *Eur J Clin Pharm* 2009;65(7):651-658.
29. **Cavallari LH**, Momary KM. Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease (Invited review). *Curr Treat Options Cardiovasc Med* 2009;11(3):191-200.
30. Nochowitz B, Shapiro NL, Nutescu EA, **Cavallari LH**. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. *Ann Pharmacother* 2009;43(7):1165-72.
31. Aquilante CL, Beitelshes AL, **Cavallari LH**, Lee CR, Maciejewski S, Momary K, Vardeny O, Zineh I. Significant articles in the field of cardiovascular pharmacogenomics. *Pharmacotherapy* 2009;29(9):1110-1151.
32. **Cavallari LH**, Groo VL, Viana MAG, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. *Pharmacotherapy* 2010;30(1):1-9.
33. **Cavallari LH**, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MAG, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans. *Clin Pharmacol Ther* 2010;87(4):459-64.
34. **Cavallari LH**, Overholser BR, Anderson D, Boyce E, Buie L, Formea CM, Gallagher JC, Hayney MS, Oestreich J. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. *Pharmacotherapy* 2010 [In press]
35. Voora D, Koboldt DC, King CR, Lenzini PA, Eby C, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Ridker P, **Cavallari LH**, Patel SR, Grice GR, Miller RD, Gage BF. A polymorphism in the VKORC1-regulator calumenin predicts higher warfarin doses. *Clin Pharmacol Ther* 2010;87(4):445-51.
36. Limdi NA, Wadelius M, **Cavallari L**, Eriksson N, Crawford D, Lee MM, Chen CH, Motsinger-Rief A, Sagreiya H, Liu N, Wu AHB, Gage BR, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ on behalf of the IWPC. Warfarin pharmacogenetics: *VKORC1* genotype as predictive as haplotype across three racial groups. *Blood* 2010 [Epub ahead of print].

Editorials and Letters

37. (**Cavallari**) **Humma LM**, Adenekan PL. Response to renin-angiotensin system antagonists in hypertensive blacks. (Letter) *J Am Coll Cardiol* 2003;42(6):1141.
38. **Cavallari L**, Vaitkus P, Groo V. Hyperkalemia after the Publication of RALES. (Letter) *New Engl J Med* 2004;351(23):2448-2450.

39. **Cavallari LH.** Pharmacogenomics in heart failure: individualizing therapy based on genotype. (Editorial) *Future Cardiol* 2006;2(2):129-131.
40. **Cavallari LH.** β -adrenergic receptor pharmacogenetics. (Editorial) *Future Cardiol* 2007;3(3):229-232.

Book Chapters

41. **Cavallari LH,** Shord SS. Pharmacogenomics. In: Schumock GT, Brundage DM, Chapman MM, et al (eds). *Science and Practice of Pharmacotherapy, Book 5, Pharmacotherapy Self-Assessment Program.* 5th ed. American College of Clinical Pharmacy: Kansas City, MO, 2005. pp. 189-214.
42. Johnson JA, **Cavallari LH.** Cardiovascular Pharmacogenomics. In: Raizada MK, Paton JFR, Katovich MJ, Kasparov S (eds). *Cardiovascular Genomics: Gene Mining for Pharmacogenomics and Gene Therapy.* Humana Press, Inc: Totawa NJ, 2005. pp. 71-94.
43. **Cavallari LH,** DiDomenico RJ. Ischemic Heart Disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT (eds). *Pharmacotherapy Principles & Practice.* 1st ed. McGraw-Hill Companies, Inc: New York, 2007. pp. 63-82. **This book received the American Medical Writers Association Distinguished 2008 Medical Book Healthcare Professionals Award.
44. **Cavallari LH,** Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach.* 7th ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 31-36.
45. Parker RB, Rogers JE, **Cavallari LH.** Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). *Pharmacotherapy: A Pathophysiologic Approach.* 7th ed. McGraw-Hill Companies, Inc: New York, 2008. pp. 173-216.
46. DiDomenico RJ, **Cavallari LH.** Stable Ischemic Heart Disease. In: Crouch M (ed). *Cardiovascular Pharmacotherapy: A Point-of-Care Guide.* 1st ed. American Society of Health-System Pharmacists, Inc: Bethesda, 2010. pp. 121-142.

Books

47. **Humma LM,** Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 1st ed. Lexi-Comp, Inc: Hudson, OH, 2003.
48. **Cavallari LH,** Ellingrod VL, Kolesar JM. Drug Information Series - Pharmacogenomics Handbook. 2nd edition. Lexi-Comp, Inc: Hudson, OH, 2005.

INVITED PRESENTATIONS

" β_2 -adrenergic receptor genetic polymorphisms and nocturnal blood pressure decline in hypertension." Cardiology PRN meeting of the 1999 Meeting of the American College of Clinical Pharmacy. Kansas City, MO. November 1999.

"Late Breaking Clinical Trials in Cardiovascular Pharmacotherapy: PRAISE II." Cardiology Focus Session at the 2000 Meeting of the American College of Clinical Pharmacy. Los Angeles, CA. November 2000.

"Current and Future Applications of Pharmacogenetics in Cardiology." Illinois/ Missouri Health-System Pharmacy Seminar. St. Louis, MO. March 2001.

"Outpatient Cardiology." Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2001 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Salt Lake City, UT. April 2001.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2001 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Salt Lake City, UT. April 2001.

“Management of Cardiovascular Diseases in the Age of Genomics.” Pharmacogenomics Curricular Track 2: Therapeutic Opportunities in the Age of Genomics, 2001 American College of Clinical Pharmacy Annual Meeting. Tampa, FL. October 2001.

“The Impact of Genetics on Drug Pharmacokinetics and Pharmacodynamics.” Pharmacokinetics/ Pharmacodynamics and Geriatrics Focus Session at the 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Outpatient Cardiology.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Savannah, GA. April 2002.

“Predicting Drug Response with Pharmacogenomics.” Keynote address for the Ohio College of Clinical Pharmacy 2002 Spring Meeting. Plains, OH. May 2002.

“Management of Cardiovascular Diseases in the Age of Genomics.” Cardiology Grand Rounds. University of Florida at Shands Hospital. Jacksonville, FL. June 2002.

“Pharmacogenomics 101.” 2002 South Carolina Society of Health-System Pharmacist Fall Symposium. Charleston, SC. October 2002.

“Predicting Drug Response with Pharmacogenomics.” Maryland Society of Health-System Pharmacists 37th Annual Seminar Pharmacotherapy Update. Cambridge, MD. October 2002.

“So you want to present an abstract at a national meeting: preparing for a poster presentation?” Career Development Curricular Track at the 2002 Annual Meeting of the American College of Clinical Pharmacy. Albuquerque, NM. October 2002.

“Genetic Influences of Responses to Cardiovascular Drugs.” Program Title: Pharmacogenomics: The Future is Now! Current Applications in Clinical Practice. 2002 Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Atlanta, GA. December 2002.

“Outpatient Cardiology.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Palm Springs, CA. April 2003.

“Critical Care.” Updates in Therapeutics: Pharmacotherapy Preparatory Course. 2003 Spring Practice and Research Forum of the American College of Clinical Pharmacy. Palm Springs, CA. April 2003.

“Optimizing Pharmacotherapy with Pharmacogenomics.” 2004 Annual Meeting of the Vermont Society of Health-System Pharmacists. Burlington, VT. March 2004.

“Genetic Influence of Aspirin Response in Stroke Patients.” Grand Rounds, Department of Neurology and Rehabilitation, University of Illinois at Chicago Medical Center. Chicago, IL. May 2004.

“The Impact of Pharmacogenetics on Drug Response and Applications to Disease Management.” 40th Annual Meeting of the Drug Information Association. Washington, DC. June 15, 2004.

“Genetic Factors and Warfarin Response.” 1st Annual Meeting of the Antithrombosis Science and Practice Retreat. University of Illinois at Chicago. Chicago, IL. August 2005.

"Genetic Influences of Warfarin Response." Cardiology Grand Rounds. University of Illinois at Chicago. Chicago, IL. November 2005.

"Genetic Influences of Warfarin Response." Department of Biopharmaceutical Sciences Research Seminar Series. University of Illinois at Chicago. Chicago, IL. March 2006.

"Personalized Management of Cardiovascular Diseases." Personalized Medicine e-Symposium (www.pm.e-symposium.com). Hosted by the International Society of Pharmacogenomics. June 2006.

"Clinical Applications of Genetic Testing." Meet the Experts Roundtable Discussion. 2006 Annual Meeting of the American College of Clinical Pharmacy. St. Louis, MO. October 2006.

"Personalized Management of Cardiovascular Diseases." Pharmacogenomics, Pharmacology, and Toxicology Forum, Department of Pathology at the Medical College of Wisconsin. Milwaukee, WI. March 2008.

"Overcoming Research Pitfalls." Center for Clinical and Translational Sciences Intensive Research Program Panel Discussion. University of Illinois at Chicago, School of Public Health. Chicago, IL. July 2008.

"Patient Specific Factors Affecting Response to Aldosterone Antagonists." Department of Pharmacy Practice/Center for Pharmacogenomics Seminar Series. University of Florida, Gainesville, FL. March 2009.

"Overcoming Research Pitfalls." Center for Clinical and Translational Sciences Intensive Research Program Panel Discussion. University of Illinois at Chicago, School of Public Health. Chicago, IL. July 2009.

"Pharmacogenomics Applications in the Real World." 2010 Spring Practice and Research Forum, American College of Clinical Pharmacy. Charlotte, NC. April 2010.

AWARDS AND HONORS

CRC Press Freshman Chemistry Award, Georgia Southern University, 1987

Kenneth L. Waters Pharmacy Scholarship, The University of Georgia, 1989

Rho Chi Certificate of Excellence, The University of Georgia, 1991

Merck Award of Academic Excellence, The University of Georgia, 1991

Fellow, American Foundation for Pharmaceutical Education for the Biomedical Research Sciences, University of Florida, 1999-2000.

Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research, University of Florida, 2000

Winner, American College of Clinical Pharmacy 2000 Annual Meeting Best Student, Resident, Fellow Paper Award Competition

American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy Faculty New Investigator, 2004

Hans Vahlteich Research Award, College of Pharmacy, University of Illinois at Chicago, 2007

Fellow, American College of Clinical Pharmacy, elected 2008

Best Paper, 2009 International Congress on Clinical Pharmacy